Worth reading
60In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
4.95
¥100 million (increase in the full-year revenue forecast versus the initial forecast)Wording
Conditional
How definitive the wording is.Contents of this document
Earnings presentationSecond quarter of the fiscal year ending February 202710 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥4,935 million
Operating profit¥641 million
Operating profit margin13 %
Results for the three months of the current quarter
Net Sales
¥2,743 million
Operating profit
¥442 million
Operating profit margin
16.1 %
R&D Expenses
¥254 million
EBITDA
¥604 million
EBITDA margin
22 %
Full-year earnings forecast
Net Sales
¥10,323 million
Operating profit
¥1,367 million
Operating profit margin
13.2 %
EBITDA
¥2,076 million
EBITDA margin
20.1 %
Semiconductor revenue
¥7,241 million
Healthcare revenue
¥1,219 million
New Business Revenue
¥1,864 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Both revenue and operating profit exceeded the forecastsBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Increase in the full-year revenue forecast for the semiconductor business¥838 million
- Increase in the full-year revenue forecast for the new business areas¥288 million
- Decrease in the full-year revenue forecast for the healthcare business¥-632 million
- Increase in the company-wide full-year revenue forecast¥495 million
- Increase in the company-wide full-year operating profit forecast¥434 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
The second-half forecast was revised based on projects with a high likelihood of orders at presentNew initiatives
- Development and application expansion of deep-ultraviolet femtosecond lasers combining Fluence's femtosecond laser technology with the company's wavelength-conversion technology
- Invited Kayama Susumu (香山晋) to serve as an advisor on management strategy
- ¥1,455 million investment to expand production capacity for Faraday rotators for data centers, plus ¥841 million in additional capital investment
Key KPIsA metric the company considers important as a management benchmark.
- EBITDA¥969 millionYear on year against the same period last year+705.0%
- EBITDA margin19.6 %Year on year against the same period last year+13.3%
- Orders received¥3,456 millionYear on year against the same period last yearRecord high for the first half
- Order Backlog¥3,390 million
- Net Debt/EBITDA2.6 timesYear on year against the same period last yearImproved from 3.7 times at the end of the previous fiscal year
- Equity ratio34.7 %Year on year against the same period last year+2.9 percentage points from the end of the previous fiscal year
Segment results
Semiconductors
Net Sales
¥3,259 million
Year on year against the same period last year+70.0%
Healthcare
Net Sales
¥874 million
Year on year against the same period last year-285.0%
New domain
Net Sales
¥800 million
Year on year against the same period last year-271.0%
Medium-term management plan targets
Fiscal year ending February 2028
Operating profit margin12 %
EBITDA margin22 %
Fiscal year ending February 2029
Net Sales13,000 %
Operating profit margin14 %
EBITDA margin23 %
Comparison with actual resultsWith an operating margin of 13.2% for the fiscal year ending February 2027, the target for the fiscal year ending February 2028 is expected to be achieved one year ahead of schedule
Market Size / Share
The 2026 semiconductor manufacturing equipment (WFE) market is forecast to grow 23.2% year on year
ShareSingle-crystal and laser products in which the company has a high market share
Orders received and order backlog
Orders received
¥3,456 million
Order backlog
¥3,390 million
Capital expenditures
Approximately just under ¥3 billion
| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | Second quarter of the fiscal year ending February 2027 |
| Net Sales | ¥4,935 million |
| Operating profit | ¥641 million |
| Operating profit margin | 13 % |
| Results for the three months of the current quarter | Net Sales ¥2,743 million / Operating profit ¥442 million / Operating profit margin 16.1 % / R&D Expenses ¥254 million / EBITDA ¥604 million / EBITDA margin 22 % |
| Full-year earnings forecast | Net Sales ¥10,323 million / Operating profit ¥1,367 million / Operating profit margin 13.2 % / EBITDA ¥2,076 million / EBITDA margin 20.1 % / Semiconductor revenue ¥7,241 million / Healthcare revenue ¥1,219 million / New Business Revenue ¥1,864 million |
| Self-assessment against the plan | Both revenue and operating profit exceeded the forecasts |
| Segment results | Semiconductors Net Sales ¥3,259 million / Year on year against the same period last year 70 % / Healthcare Net Sales ¥874 million / Year on year against the same period last year ¥-285 million / New domain Net Sales ¥800 million / Year on year against the same period last year ¥-271 million |
| Breakdown of Factors Affecting the Change | Factors Increase in the full-year revenue forecast for the semiconductor business / Amount ¥838 million, Factors Increase in the full-year revenue forecast for the new business areas / Amount ¥288 million, Factors Decrease in the full-year revenue forecast for the healthcare business / Amount ¥-632 million, Factors Increase in the company-wide full-year revenue forecast / Amount ¥495 million, Factors Increase in the company-wide full-year operating profit forecast / Amount ¥434 million |
| Key KPIs | Indicator name EBITDA / Value ¥969 million / Year on year against the same period last year ¥705 million, Indicator name EBITDA margin / Value 19.6 % / Year on year against the same period last year 13.3 %, Indicator name Orders received / Value ¥3,456 million / Year on year against the same period last year Record high for the first half, Indicator name Order Backlog / Value ¥3,390 million / Year on year against the same period last year Not disclosed, Indicator name Net Debt/EBITDA / Value 2.6 times / Year on year against the same period last year Improved from 3.7 times at the end of the previous fiscal year, Indicator name Equity ratio / Value 34.7 % / Year on year against the same period last year +2.9 percentage points from the end of the previous fiscal year |
| Assumptions Underlying the Business Outlook | The second-half forecast was revised based on projects with a high likelihood of orders at present |
| Medium-term management plan targets | Fiscal year ending February 2028 Operating profit margin 12 % / EBITDA margin 22 % / Fiscal year ending February 2029 Net Sales 13,000 % / Operating profit margin 14 % / EBITDA margin 23 % / Comparison with actual results With an operating margin of 13.2% for the fiscal year ending February 2027, the target for the fiscal year ending February 2028 is expected to be achieved one year ahead of schedule |
| Capital expenditures | Approximately just under ¥3 billion |
| Orders received and order backlog | Orders received ¥3,456 million / Order backlog ¥3,390 million |
| Market Size / Share | Market Size The 2026 semiconductor manufacturing equipment (WFE) market is forecast to grow 23.2% year on year / Share Single-crystal and laser products in which the company has a high market share |
| New initiatives | Development and application expansion of deep-ultraviolet femtosecond lasers combining Fluence's femtosecond laser technology with the company's wavelength-conversion technology, Invited Kayama Susumu (香山晋) to serve as an advisor on management strategy, ¥1,455 million investment to expand production capacity for Faraday rotators for data centers, plus ¥841 million in additional capital investment |
Items this document does not state (14)
Ordinary incomeNet incomeGross Profit MarginSelling, general and administrative expensesProgress against full-year forecastUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Increased shipments of single-crystal and laser products in the semiconductor business and Faraday rotators for data centers in the new business areas drove revenue growth. In the healthcare business, the company revised its second-half forecast based on projects with a high likelihood of orders, in response to the deterioration in the procurement environment for key raw materials and surging prices.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.